Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.24 USD | -1.44% | -7.09% | +155.42% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+155.42% | 968M | |
+14.06% | 118B | |
+12.50% | 106B | |
-4.50% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.34% | 15.56B | |
+4.06% | 13.63B | |
+27.39% | 12.27B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump